Navigation Links
Ferring Announces It Will Present Phase 3 Data for Cervical Ripening Agent at American College of Obstetricians and Gynecologists Annual Clinical Meeting
Date:5/2/2013

NEW ORLEANS, May 2, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present efficacy and safety data from its Phase 3 EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 61st annual clinical meeting of the American College of Obstetricians and Gynecologists in New Orleans, May 4 – 8, 2013.

Studies accepted for presentation include:

  • A poster presentation on Tues., May 7 (3:00 p.m. – 4:00 p.m. EDT), titled "Reduced Time to Delivery and Significantly Less Antibiotic Use" (lead author: Deborah A. Wing , M.D.; University of California, Irvine; Irvine, CA); and
  • A poster presentation on Tues., May 7 (3:00 p.m. – 4:00 p.m. EDT), titled "Misoprostol Vaginal Insert Reduces Time to Delivery in Nulliparous and Parous Women" (lead author: R. Lamar Parker , M.D.; Lyndhurst Clinical Research, Winston-Salem, NC).

*The EXPEDITE Study: A Phase 3, double blind, randomized, multicenter study of EXogenous Prostaglandin comparing the Efficacy and safety of the MVI 200 mcg to the Dinoprostone vaginal Insert for reducing Time to vaginal delivery in pregnant women at tErm.

For further information, contact:
Leila Boukassi
MSL New York
Leila.Boukassi@mslgroup.com; 646.500.7735

About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven speciality biopharmaceutical company, active in global markets. The company identifies, develops and markets innovative products in the areas of general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.


'/>"/>
SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
2. Ferring Pharmaceuticals Inc. Named 10th Fastest Growing New Jersey Company
3. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
4. Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016  "Blood Tests replace Surgical ... ....." The Diagnostic, Monitoring and Screening Test ... diagnostics is occurring using in vitro blood testing ... with impressive backing, has announced a single blood ... moving faster than the market. New technology that ...
(Date:12/6/2016)... 2016 Diabetes & Obesity Drug Development Pipeline ... disease cluster is currently dominated by therapeutics indicated for ... mellitus (T2DM), and the majority of the pipeline, in ... attributable to these indications. While products indicated for obesity ... are a large number of these products in the ...
(Date:12/6/2016)... Dec. 6, 2016 Anaplastic Oligoastrocytoma - ... Markets Direct,s latest Pharmaceutical and Healthcare disease pipeline ... provides an overview of the Anaplastic Oligoastrocytoma (Oncology) ... tumor that forms when two types of cells ... increase in number to form a mass. These ...
Breaking Medicine Technology:
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “The Road ... is an everyday trial, not a one hour a week showing of hands. “The ... businessman. , Tom begins, “Perhaps you are familiar with the brass ring that you ...
(Date:12/7/2016)... NORFOLK, Va. (Dec. 3, 2016) , ... (PRWEB) ... ... the nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, ... work in New Mexico with a patient engagement program. New Mexico has more ...
(Date:12/7/2016)... , ... December 07, 2016 , ... "Hacking into my ... had described him as 'a genius.'" Thus begins "Margaret in Berlin," Book Twelve in ... published by Wyston Books, Inc. These novels narrate the lives of a ...
(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to reduce the effects ... water or limiting their exposure to the sun, according to a November 30 ... Hills Physicians (BHP) notes that, while preventive measures to help keep ourselves looking our ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... prescriptive health insights for population health management, announces today a strategic relationship ... leverage CitiusTech’s cloud-hosted clinical rules engine that offers advanced Clinical Quality Measures ...
Breaking Medicine News(10 mins):